A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

Clinical trial NCT06908928 · RECRUITING

Trial details

NCT number: NCT06908928
Sponsor: Mabwell (Shanghai) Bioscience Co., Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Triple Negative Breast Cancer

Start date: 2025-08-11
Primary completion: 2027-05-01
Enrollment: 52

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.